{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:39:17Z","timestamp":1788910757324,"version":"build-2803163510"},"reference-count":39,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"name":"Commercialization Australia","award":["CAU05922"],"award-info":[{"award-number":["CAU05922"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["513781"],"award-info":[{"award-number":["513781"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["1042231"],"award-info":[{"award-number":["1042231"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["1058260"],"award-info":[{"award-number":["1058260"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To assess the ability of plasma apolipoprotein (apo) A-IV (apoA4), apo C-III, CD5 antigen-like (CD5L), complement C1q subcomponent subunit B (C1QB), complement factor H\u2013related protein 2, and insulin-like growth factor binding protein 3 (IBP3) to predict rapid decline in estimated glomerular filtration rate (eGFR) in type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Mass spectrometry was used to measure baseline biomarkers in 345 community-based patients (mean age 67.0 years, 51.9% males) from the Fremantle Diabetes Study Phase II (FDS2). Multiple logistic regression was used to determine clinical predictors of rapid eGFR decline trajectory defined by semiparametric group-based modeling over a 4-year follow-up period. The incremental benefit of each biomarker was then assessed. Similar analyses were performed for a \u226530% eGFR fall, incident chronic kidney disease (eGFR &amp;lt;60 mL\/min\/1.73 m2), and eGFR decline of \u22655 mL\/min\/1.73 m2\/year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Based on eGFR trajectory analysis, 35 participants (10.1%) were defined as \u201crapid decliners\u201d (mean decrease 2.9 mL\/min\/1.73 m2\/year). After adjustment for clinical predictors, apoA4, CD5L, and C1QB independently predicted rapid decline (odds ratio 2.40 [95% CI 1.24\u20134.61], 0.52 [0.29\u20130.93], and 2.41 [1.14\u20135.11], respectively) and improved model performance and fit (P &amp;lt; 0.001), discrimination (area under the curve 0.75\u20130.82, P = 0.039), and reclassification (net reclassification index 0.76 [0.63\u20130.89]; integrated discrimination improvement 6.3% [2.1\u201310.4%]). These biomarkers and IBP3 contributed to improved model performance in predicting other indices of rapid eGFR decline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The current study has identified novel plasma biomarkers (apoA4, CD5L, C1QB, and IBP3) that may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in type 2 diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-0911","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T00:25:34Z","timestamp":1504052734000},"page":"1548-1555","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":76,"title":["Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II"],"prefix":"10.2337","volume":"40","author":[{"given":"Kirsten E.","family":"Peters","sequence":"first","affiliation":[{"name":"Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Fremantle, Western Australia, Australia"},{"name":"Proteomics International, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Davis","sequence":"additional","affiliation":[{"name":"Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Fremantle, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ito","sequence":"additional","affiliation":[{"name":"Proteomics International, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaye","family":"Winfield","sequence":"additional","affiliation":[{"name":"Proteomics International, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stoll","sequence":"additional","affiliation":[{"name":"Proteomics International, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Bringans","sequence":"additional","affiliation":[{"name":"Proteomics International, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lipscombe","sequence":"additional","affiliation":[{"name":"Proteomics International, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0749-7411","authenticated-orcid":false,"given":"Timothy M.E.","family":"Davis","sequence":"additional","affiliation":[{"name":"Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Fremantle, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"2022031301530208200_B1","unstructured":"United States Renal Data System. 2015 annual data report [article online], 2015. Available from https:\/\/www.usrds.org\/2015\/view\/. Accessed March 2017"},{"key":"2022031301530208200_B2","unstructured":"Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. Available from https:\/\/www.cdc.gov\/diabetes\/pubs\/pdf\/kidney_factsheet.pdf. Accessed March 2017"},{"key":"2022031301530208200_B3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/j.ajkd.2013.06.016","article-title":"Day-to-day variability in spot urine albumin-creatinine ratio","volume":"62","author":"Naresh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2022031301530208200_B4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdiacomp.2012.09.010","article-title":"Normoalbuminuric diabetic kidney disease in the U.S. population","volume":"27","author":"Mottl","year":"2013","journal-title":"J Diabetes Complications"},{"key":"2022031301530208200_B5","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2215\/CJN.10321014","article-title":"Risk prediction for early CKD in type 2 diabetes","volume":"10","author":"Dunkler","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031301530208200_B6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4239\/wjd.v7.i14.290","article-title":"Early detection of diabetic kidney disease: present limitations and future perspectives","volume":"7","author":"Lin","year":"2016","journal-title":"World J Diabetes"},{"key":"2022031301530208200_B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11892-015-0708-0","article-title":"Diabetic kidney disease in adolescents with type 2 diabetes: new insights and potential therapies","volume":"16","author":"Bjornstad","year":"2016","journal-title":"Curr Diab Rep"},{"key":"2022031301530208200_B8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2015.199","article-title":"Biomarkers of rapid chronic kidney disease progression in type 2 diabetes","volume":"88","author":"Looker","year":"2015","journal-title":"Kidney Int"},{"key":"2022031301530208200_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022031301530208200_B10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/dme.12447","article-title":"Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus","volume":"31","author":"Pena","year":"2014","journal-title":"Diabet Med"},{"key":"2022031301530208200_B11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1093\/ndt\/gfu255","article-title":"A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2022031301530208200_B12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2337\/dc16-1571","article-title":"Association of circulating biomarkers (adrenomedullin, TNFR1, and NT-proBNP) with renal function decline in patients with type 2 diabetes: a French prospective cohort","volume":"40","author":"Saulnier","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031301530208200_B13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2022031301530208200_B14","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2022031301530208200_B15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-16-0327","article-title":"The relationship between estimated glomerular filtration rate trajectory and all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study","volume":"175","author":"Davis","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2022031301530208200_B16","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2337\/dc15-2607","article-title":"Dynamic changes in renal function are associated with major cardiovascular events in patients with type 2 diabetes","volume":"39","author":"Ragot","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301530208200_B17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ije\/dys065","article-title":"Cohort profile: the Fremantle Diabetes Study","volume":"42","author":"Davis","year":"2013","journal-title":"Int J Epidemiol"},{"key":"2022031301530208200_B18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022031301530208200_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euprot.2016.12.001","article-title":"Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease","volume":"14","author":"Bringans","year":"2017","journal-title":"EuPA Open Proteom"},{"key":"2022031301530208200_B20"},{"key":"2022031301530208200_B21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"2022031301530208200_B22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/heartjnl-2011-301246","article-title":"Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker","volume":"98","author":"Moons","year":"2012","journal-title":"Heart"},{"key":"2022031301530208200_B23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"key":"2022031301530208200_B24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2215\/CJN.09590911","article-title":"New metrics for assessing diagnostic potential of candidate biomarkers","volume":"7","author":"Pickering","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031301530208200_B25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1681\/ASN.V132461","article-title":"Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure","volume":"13","author":"Kronenberg","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2022031301530208200_B26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/joim.12380","article-title":"Association between apolipoprotein A-IV concentrations and chronic kidney disease in two large population-based cohorts: results from the KORA studies","volume":"278","author":"Stangl","year":"2015","journal-title":"J Intern Med"},{"key":"2022031301530208200_B27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12967-015-0712-9","article-title":"Differential urinary glycoproteome analysis of type 2 diabetic nephropathy using 2D-LC-MS\/MS and iTRAQ quantification","volume":"13","author":"Guo","year":"2015","journal-title":"J Transl Med"},{"key":"2022031301530208200_B28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1681\/ASN.2005070733","article-title":"Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study","volume":"17","author":"Boes","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2022031301530208200_B29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000371426","article-title":"Renal C3 complement component: feed forward to diabetic kidney disease","volume":"41","author":"Kelly","year":"2015","journal-title":"Am J Nephrol"},{"key":"2022031301530208200_B30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1189\/jlb.3RU0215-074R","article-title":"AIM\/CD5L: a key protein in the control of immune homeostasis and inflammatory disease","volume":"98","author":"Sanjurjo","year":"2015","journal-title":"J Leukoc Biol"},{"key":"2022031301530208200_B31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm.4012","article-title":"Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice","volume":"22","author":"Arai","year":"2016","journal-title":"Nat Med"},{"key":"2022031301530208200_B32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1530\/EC-12-0053","article-title":"IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes","volume":"1","author":"Narayanan","year":"2012","journal-title":"Endocr Connect"},{"key":"2022031301530208200_B33","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1046\/j.1523-1755.1999.00798.x","article-title":"Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure","volume":"56","author":"Frystyk","year":"1999","journal-title":"Kidney Int"},{"key":"2022031301530208200_B34","doi-asserted-by":"crossref","first-page":"e0120995","DOI":"10.1371\/journal.pone.0120995","article-title":"A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes","volume":"10","author":"Pena","year":"2015","journal-title":"PLoS One"},{"key":"2022031301530208200_B35","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/HJH.0000000000000685","article-title":"Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes","volume":"33","author":"Pena","year":"2015","journal-title":"J Hypertens"},{"key":"2022031301530208200_B36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.kint.2017.02.010","article-title":"Improved clinical trial enrollment criterion to\u00a0identify patients with diabetes at risk of end-stage renal disease","volume":"92","author":"Yamanouchi","year":"2017","journal-title":"Kidney Int"},{"key":"2022031301530208200_B37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diabet.2016.03.006","article-title":"The association between endostatin and kidney disease and mortality in patients with type 2 diabetes","volume":"42","author":"Carlsson","year":"2016","journal-title":"Diabetes Metab"},{"key":"2022031301530208200_B38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jdiacomp.2016.10.030","article-title":"Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes","volume":"31","author":"Viazzi","year":"2017","journal-title":"J Diabetes Complications"},{"key":"2022031301530208200_B39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc17-0911","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/11\/1548\/551979\/dc170911.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/11\/1548\/551979\/dc170911.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:56:56Z","timestamp":1647151016000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/11\/1548\/36999\/Identification-of-Novel-Circulating-Biomarkers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,8,29]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-0911","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}